[go: up one dir, main page]

AR031117A1 - Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica - Google Patents

Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica

Info

Publication number
AR031117A1
AR031117A1 ARP010103573A ARP010103573A AR031117A1 AR 031117 A1 AR031117 A1 AR 031117A1 AR P010103573 A ARP010103573 A AR P010103573A AR P010103573 A ARP010103573 A AR P010103573A AR 031117 A1 AR031117 A1 AR 031117A1
Authority
AR
Argentina
Prior art keywords
biliar
lipase
preparation
pharmaceutical combination
biliar acid
Prior art date
Application number
ARP010103573A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR031117A1 publication Critical patent/AR031117A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un inhibidor de lipasa y de un secuestrante de ácido biliar que es para la preparacion de un medicamento para la prevencion y tratamiento de las enfermedades que se asocian con niveles elevados de colesterol plasmático; en especial al uso de un inhibidor de lipasa, por ejemplo, orlistat, y un secuestrante de ácido biliar aceptable para uso farmacéutico para el tratamiento de enfermedades que se relacionan con los niveles elevados de colesterol plasmático; y una combinacion farmacéutica.
ARP010103573A 2000-07-28 2001-07-26 Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica AR031117A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00116392 2000-07-28

Publications (1)

Publication Number Publication Date
AR031117A1 true AR031117A1 (es) 2003-09-10

Family

ID=8169383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103573A AR031117A1 (es) 2000-07-28 2001-07-26 Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica

Country Status (17)

Country Link
US (3) US6562329B2 (es)
EP (1) EP1307263B1 (es)
JP (2) JP4772264B2 (es)
KR (1) KR100556324B1 (es)
CN (1) CN1261094C (es)
AR (1) AR031117A1 (es)
AT (1) ATE293477T1 (es)
AU (2) AU8969601A (es)
BR (1) BR0112800A (es)
CA (1) CA2416900C (es)
DE (1) DE60110232T2 (es)
DK (1) DK1307263T3 (es)
ES (1) ES2240516T3 (es)
MX (1) MXPA03000694A (es)
PT (1) PT1307263E (es)
WO (1) WO2002009814A2 (es)
ZA (1) ZA200300454B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240516T3 (es) * 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
JP4353414B2 (ja) * 2001-07-30 2009-10-28 田辺三菱製薬株式会社 食後過血糖改善剤
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
KR101547925B1 (ko) * 2005-09-15 2015-08-27 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
US8067402B2 (en) * 2005-12-12 2011-11-29 Allaccem, Inc. Methods and systems for coating an oral surface
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
ITRM20060204A1 (it) 2006-04-10 2007-10-11 Vincenzo Savica Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche
EP2478895A3 (en) 2006-12-22 2012-12-19 Ironwood Pharmaceuticals, Inc. Compositions for treating esophageal disorders
WO2008103847A2 (en) 2007-02-21 2008-08-28 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
CN101791296B (zh) * 2010-01-17 2012-08-29 山东新时代药业有限公司 一种奥利司他片剂及其制备方法
LT2568827T (lt) * 2010-05-14 2018-08-27 Omega Pharma Innovation & Development Nv Kompozicija, skirta dietinės mitybos riebalų absorbavimo mažinimui
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
KR102271821B1 (ko) * 2020-12-18 2021-07-01 주식회사 엔테로바이옴 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물
JP2024500188A (ja) * 2020-12-22 2024-01-04 サイトゼリックス，インク． 胆道送達方法、その使用のための組成物及びキット
CN113057340B (zh) * 2021-04-29 2024-01-19 南京邮电大学 一种菌菇膳食纤维改性方法
CN116018147A (zh) * 2021-08-24 2023-04-25 中美华世通生物医药科技(武汉)股份有限公司 用于治疗高尿酸血症的聚合物、组合物和方法
WO2023023938A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
KR19980702533A (ko) * 1995-12-26 1998-07-15 도리이 신이찌로 프로시아니딘을 유효성분으로 하는 항비만제
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
ATE293970T1 (de) * 1998-08-14 2005-05-15 Hoffmann La Roche Lipasehemmer enthaltende pharmazeutische zusammensetzungen
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AU2001289699B2 (en) * 2000-07-28 2006-06-01 Cheplapharm Arzneimittel Gmbh New pharmaceutical composition
ES2240516T3 (es) * 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.

Also Published As

Publication number Publication date
JP4772264B2 (ja) 2011-09-14
EP1307263B1 (en) 2005-04-20
CN1444496A (zh) 2003-09-24
DE60110232D1 (de) 2005-05-25
JP2004505066A (ja) 2004-02-19
AU8969601A (en) 2002-02-13
BR0112800A (pt) 2003-07-01
DK1307263T3 (da) 2005-08-22
KR20030069978A (ko) 2003-08-27
ES2240516T3 (es) 2005-10-16
US20060189574A1 (en) 2006-08-24
WO2002009814A2 (en) 2002-02-07
US20020042395A1 (en) 2002-04-11
US20030138396A1 (en) 2003-07-24
AU2001289696B2 (en) 2006-07-06
CN1261094C (zh) 2006-06-28
MXPA03000694A (es) 2003-06-04
US6562329B2 (en) 2003-05-13
ATE293477T1 (de) 2005-05-15
DE60110232T2 (de) 2006-01-19
CA2416900A1 (en) 2002-02-07
EP1307263A2 (en) 2003-05-07
ZA200300454B (en) 2004-04-16
KR100556324B1 (ko) 2006-03-03
WO2002009814A3 (en) 2002-04-18
JP2009108062A (ja) 2009-05-21
PT1307263E (pt) 2005-08-31
CA2416900C (en) 2007-07-03

Similar Documents

Publication Publication Date Title
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
ID22746A (id) Senyawa-senyawa baru
ES2181614T3 (es) Sulfonilfenilheterociclos sustituidos como inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
MA28102A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
AR003415A1 (es) Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
ES2166823T3 (es) Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
GT200100201A (es) Derivados de pirazol para el tratamiento der enfermedades viricas.
DE60233261D1 (de) Inhibitoren von humanem adam-10
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ATE319715T1 (de) Antikonvulsive pseudofructopyranose sulfamate
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure